Drug Resistant Tuberculosis in Saudi Arabia: an Analysis of Surveillance Data 2014-2015

Overview

Journal Antimicrob Resist Infect Control

Publisher Biomed Central

Specialty Infectious Diseases

Date 2018 Feb 2

PMID 29387346

Citations 15

Authors

Maha Al Ammari

Abdulrahman Al Turaiki

Mohammed Al Essa

Abdulhameed M Kashkary

Sara A Eltigani

Anwar E Ahmed

Affiliations

Soon will be listed here.

Abstract

Background: There is limited data that investigates the national rates of drug-resistant tuberculosis (TB) in Saudi Arabia.This study aimed to estimate the rates of multi-drug-resistant tuberculosis (MDR-TB), rifampicin-resistant tuberculosis (RR-TB), and monoresistance (MR) in Saudi Arabia.

Methods: A retrospective cohort study was conducted on all TB cases reported to the National TB Control and Prevention Program (NTCPP) registry at the Saudi Ministry of Health between January 1, 2014 and December 31, 2015. A total of 2098 TB patients with positive TB cultures were included in the study. Subgroup analyses and multivariate binary logistic regression models were performed with IBM SPSS 23.0.

Results: Of the total TB cases, 4.4% (95% CI: 3.59%-5.40%) were found to have MDR-TB. The rates of MR were 3.8% (95% CI: 2.99%-4.67%) for ethambutol, 5.4% (95% CI: 4.50%-6.49%) for pyrazinamide, 10.2% (95% CI: 5.89%-11.52%) for isoniazid, 11% (95% CI: 9.70%-12.43%) for streptomycin, and 5.9% (95% CI: 4.90%-6.96%) for rifampicin. The high rates of MDR and RR-TB were found among the younger age group, female gender, and those who had a previous history of TB. We also discovered that renal failure tends to increase the risk of rifampicin resistance.

Conclusions: National TB data in Saudi Arabia shows that the rate of MDR-TB was similar to the global rate reported by the World Health Organization (WHO). It is a relatively high rate as compared to Western countries. The proportion of MDR/RR-TB patients tends to be higher in the younger age group, female gender, and in patients with a previous history of TB treatment. Effective strategies for prevention of all multi-drug-resistant TB cases are warranted.

Citing Articles

Prevalence, patterns, and determinants of drug-resistant tuberculosis in Gulf Cooperation Council countries: an updated systematic review.

Alibrahim A, Alqahtani H, Thirunavukkarasu A, Qazi I PeerJ. 2024; 12:e18628.

PMID: 39619190 PMC: 11608559. DOI: 10.7717/peerj.18628.

Epidemiology of tuberculosis in Saudi Arabia following the implementation of end tuberculosis strategy: Analysis of the surveillance data 2015-2019.

Alawi M, Alserehi H, Ali A, Albalawi A, Alanizi M, Nabet F Saudi Med J. 2024; 45(1):60-68.

PMID: 38220236 PMC: 10807673. DOI: 10.15537/smj.2024.45.1.20230424.

Evaluating the Sensitivity of Different Molecular Techniques for Detecting Complex in Patients with Pulmonary Infection.

Hemeg H, Albulushi H, Ozbak H, Ali H, Alahmadi E, Almutawif Y Pol J Microbiol. 2023; 72(4):421-431.

PMID: 37934050 PMC: 10725165. DOI: 10.33073/pjm-2023-040.

Epidemiological characteristics and risk factors of multidrug-resistant tuberculosis in Luoyang, China.

Wang Z, Hou Y, Guo T, Jiang T, Xu L, Hu H Front Public Health. 2023; 11:1117101.

PMID: 37228738 PMC: 10203519. DOI: 10.3389/fpubh.2023.1117101.

A Saudi Arabian Public Health Perspective of Tuberculosis.

Saati A, Khurram M, Faidah H, Haseeb A, Iriti M Int J Environ Res Public Health. 2021; 18(19).

PMID: 34639342 PMC: 8508237. DOI: 10.3390/ijerph181910042.

References

Allen A, Minozzi G, Glass E, Skuce R, McDowell S, Woolliams J . Bovine tuberculosis: the genetic basis of host susceptibility. Proc Biol Sci. 2010; 277(1695):2737-45. PMC: 2981996. DOI: 10.1098/rspb.2010.0830. View

Cambau E, Viveiros M, Machado D, Raskine L, Ritter C, Tortoli E . Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study. J Antimicrob Chemother. 2015; 70(3):686-96. DOI: 10.1093/jac/dku438. View

Abouzeid M, Zumla A, Felemban S, Alotaibi B, OGrady J, Memish Z . Tuberculosis trends in Saudis and non-Saudis in the Kingdom of Saudi Arabia--a 10 year retrospective study (2000-2009). PLoS One. 2012; 7(6):e39478. PMC: 3380015. DOI: 10.1371/journal.pone.0039478. View

Alzeer A, Mashlah A, Fakim N, Al-Hedaithy M, Al-Majed S, Jamjoom G . Tuberculosis is the commonest cause of pneumonia requiring hospitalization during Hajj (pilgrimage to Makkah). J Infect. 1998; 36(3):303-6. DOI: 10.1016/s0163-4453(98)94315-8. View

Laserson K, Thorpe L, Leimane V, Weyer K, Mitnick C, Riekstina V . Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005; 9(6):640-5. View

Asaad A, Alqahtani J . Primary anti-tuberculous drugs resistance of pulmonary tuberculosis in Southwestern Saudi Arabia. J Infect Public Health. 2012; 5(4):281-5. DOI: 10.1016/j.jiph.2012.03.005. View

Villarino M, Geiter L, Simone P . The multidrug-resistant tuberculosis challenge to public health efforts to control tuberculosis. Public Health Rep. 1992; 107(6):616-25. PMC: 1403711. View

Faustini A, Hall A, Perucci C . Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2005; 61(2):158-63. PMC: 2104570. DOI: 10.1136/thx.2005.045963. View

Main C, Ying E, Wang E . How much does it cost to manage paediatric tuberculosis? One-year experience from The Hospital for Sick Children. Can J Infect Dis. 2012; 9(6):354-8. PMC: 3250878. DOI: 10.1155/1998/507497. View

10.

McGowan Jr J, Blumberg H . Inner-city tuberculosis in the USA. J Hosp Infect. 1995; 30 Suppl:282-95. DOI: 10.1016/0195-6701(95)90031-4. View

11.

Chaudhry L, Rambhala N, Al-Shammri A, Al-Tawfiq J . Patterns of antituberculous drug resistance in Eastern Saudi Arabia: a 7-year surveillance study from 1/2003 to 6/2010. J Epidemiol Glob Health. 2013; 2(1):57-60. PMC: 7320363. DOI: 10.1016/j.jegh.2011.10.001. View

12.

Al-Orainey I, Alhedaithy M, Alanazi A, Barry M, Almajid F . Tuberculosis incidence trends in Saudi Arabia over 20 years: 1991-2010. Ann Thorac Med. 2013; 8(3):148-52. PMC: 3731856. DOI: 10.4103/1817-1737.114303. View

13.

Ruddy M, Balabanova Y, Graham C, Fedorin I, Malomanova N, Elisarova E . Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia. Thorax. 2005; 60(2):130-5. PMC: 1747303. DOI: 10.1136/thx.2004.026922. View

14.

Elhassan M, Hemeg H, Elmekki M, Turkistani K, Abdul-Aziz A . Burden of Multidrug Resistant Mycobacterium tuberculosis Among New Cases in Al-Madinah Al-Monawarah, Saudi Arabia. Infect Disord Drug Targets. 2016; 17(1):14-23. PMC: 5750745. DOI: 10.2174/1871526517666161116104242. View

15.

Karabay O, Otkun M, Akata F, Karlikaya C, Tugrul M, Dundar V . Antituberculosis drug resistance and associated risk factors in the European section of Turkey. Indian J Chest Dis Allied Sci. 2004; 46(3):171-7. View

16.

Jain A, Dixit P . Multidrug-resistant to extensively drug resistant tuberculosis: what is next?. J Biosci. 2009; 33(4):605-16. DOI: 10.1007/s12038-008-0078-8. View

17.

Mulu W, Mekonnen D, Yimer M, Admassu A, Abera B . Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State. Afr Health Sci. 2015; 15(2):368-77. PMC: 4480497. DOI: 10.4314/ahs.v15i2.9. View

18.

Cegielski J . Extensively drug-resistant tuberculosis: "there must be some kind of way out of here". Clin Infect Dis. 2010; 50 Suppl 3:S195-200. DOI: 10.1086/651491. View

19.

Fiebig L, Kollan C, Hauer B, Gunsenheimer-Bartmeyer B, An der Heiden M, Hamouda O . HIV-prevalence in tuberculosis patients in Germany, 2002-2009: an estimation based on HIV and tuberculosis surveillance data. PLoS One. 2012; 7(11):e49111. PMC: 3492302. DOI: 10.1371/journal.pone.0049111. View

20.

Al-Hajoj S, Varghese B, Shoukri M, Al-Omari R, Al-Herbwai M, AlRabiah F . Epidemiology of antituberculosis drug resistance in Saudi Arabia: findings of the first national survey. Antimicrob Agents Chemother. 2013; 57(5):2161-6. PMC: 3632946. DOI: 10.1128/AAC.02403-12. View